Introduction
Stenotrophomonas maltophilia is an aerobic glucose nonfermentative Gram-negative bacillus ubiquitously present in the environment. It has emerged as a pathogen in healthcare associated infections (HAIs), especially in immunocompromised patients. S. maltophilia has a variety of clinical presentations, including bacteremia, respiratory tract infections, urinary tract infections, skin and soft tissue infections, endocarditis, and meningitis. 4e7 Respiratory tract infection, especially ventilator-associated pneumonia, is most frequently seen in S. maltophilia infections. 8 Risk factors associated with S. maltophilia colonization and infection include hematologic malignancy, admission to intensive care units, use of central venous catheters, recent surgery, ventilator usage, and previous therapy with broadspectrum antibiotics, especially carbapenems. 9e13 Many antibiotics, including carbapenems, are not effective against S. maltophilia, making infections a challenge to treat. 1, 14 Trimethoprimesulfamethoxazole (TMP/ SMX) and levofloxacin are the most common antibiotics used to treat the S. maltophilia infections; however, according to the Taiwan Surveillance of Antimicrobial Resistance program, resistance to ceftazidime, TMP/SMX, levofloxacin, and ticarcillin/clavulanic acid has been increasing.
15e17 Antibiotic efflux pumps, such as SmeABC and SmeDEF, have been reported to play a role in S. maltophilia resistance to fluoroquinolones. In addition, SpgM, a phosphoglucomutase, has also been associated with fluoroquinolone resistance in S. maltophilia. 18, 19 In this study, we assessed the roles of resistant genes for efflux pumps and phosphoglucomutase for levofloxacin resistance among clinical isolates of S. maltophilia. We also evaluated the risk factors associated with levofloxacin resistance in S. maltophilia infections using a caseecontrol study.
Methods

Setting
The Hsin-Chu branch of the National Taiwan University Hospital is a regional hospital with a capacity of 694 beds. This was a case-control study.
Bacterial isolates
We prospectively collected S. maltophilia isolated from the respiratory tracts specimens of adult patients from January 1, 2010 to June 30, 2011 for this case-control study. If several isolates of S. maltophilia were obtained from a single patient, only the first to be isolated was included in the study. Patients who were not admitted in our hospital were excluded from the study. All of the isolates were identified by conventional biochemical identification methods and were confirmed by polymerase chain reaction (PCR) analysis of the SM1 and SM4 regions of the S. maltophilia 23S rRNA gene. 20 
Susceptibility testing
S. maltophilia is resistant to many drugs, including most of penicillins, cephalosporins, and carbapenems, so we focused on drugs commonly used to treat S. maltophilia infections. Because our hospital does not stock them, monobactam-class antibiotics were not used in this study. Susceptibility to various antimicrobial agents, including ciprofloxacin, TMP/SMX, tigecycline, and colistin were determined by minimal inhibition concentrations using the Clinical and Laboratory Standards Institute's reference microbroth dilution method. 21 Case groups were defined as patients who had levofloxacin-resistant S. maltophilia infections. Control groups were defined as patients who had levofloxacinsusceptible S. maltophilia infections. Patient medical records collected by chart review included age, sex, underlying disease, previous medical history, and previous antibiotics usage. Previous antibiotics usage was defined as administration of antibiotic less than 15 days prior to when S. maltophilia was isolated from the patient's sputum. Drug resistant genes, such as SmeA, SmeD, and SpgM, were analyzed in these bacteria by PCR analysis. 18 Institutional review board approval was obtained for this study (ethical approval number HCGH99IRB-12).
Identification of SmeA, SmeD, and SpgM genes
Cells were prepared and inoculated onto a MuellereHinton agar plate as in the agar dilution method. Following overnight culture, cells were collected to make a 1.5 mL suspension of optical density at 550 nm (OD 550 ) Z 1.0. RNA was prepared using an RNA-Be Kit (Tel-Test Inc., Friendswood, TX, USA) and cDNA was obtained with the SuperScript First-Strand Synthesis System for reverse transcription-PCR (Invitrogen Corp., Carlsbad, CA, USA) using random hexamers. Primer pairs 5
0 were used for PCR to detect the expression of SmeA, SmeD, and SpgM, respectively, using cDNA of 16S rRNA as an internal control.
Results
Eighty patients were originally recruited for this study. Twenty-seven had levofloxacin-resistant S. maltophilia infections. However, four patients were excluded because they were not admitted to the hospital; two of these cases demonstrated levofloxacin-resistance. Therefore, a total of 76 patients were enrolled in the study, 25 with levofloxacinresistant and 51 with levofloxacin-sensitive S. maltophilia infections.
The basic demographic data, underlying diseases, and other potential risk factors for patients in this study are shown in Table 1 . Previous antibiotic treatment with firstor second-generation cephalosporin was observed more often in the levofloxacin-susceptible group; by contrast, previous piperacillin/tazobactam use was reported more often in the levofloxacin-resistant group.
Three drug resistance genes were analyzed in patient bacterial isolates, including SmeA, SmeD, and SpgM (Table  1) ; however, no significant associations were found in either group.
We also tested levofloxacin-resistant S. maltophilia for resistance to other antibiotics. The results are shown in Table 1 . Similarly, several antibiotics, including ciprofloxacin, TMP/SMX, tigecycline, and colistin had lower resistance rates in bacteria sensitive to levofloxacin. Genes associated with resistance towards other antibiotics are shown in Table 2 . Only TMP/SMX treatment showed increased resistance rates in SmeD-and SpgM-negative groups.
Discussion
Fihman et al 22 reported that risk factors for S. maltophilia infection include: immunocompromised status, central venous catheter insertion in intensive care units, and hospitalization within the previous 90 days. Other studies have discussed risk factors for S. maltophilia bacteremia; however, to our knowledge, none have reported risk factors for fluoroquinolone-resistant S. maltophilia infections. 23 In contrast to other studies, we did not find underlying diseases to be a predisposing factor for levofloxacin-resistant S. maltophilia infection. Although patients with diabetes mellitus had a higher rate of levofloxacin-resistant S. maltophilia infection, this rate was not statistically significant.
Patients who had previously received piperacillin/tazobactam antibiotic treatments had higher rates of levofloxacin resistance; however, previous use of first-or second-generation cephalosporin had lower rates of levofloxacin resistance. The mechanism for resistance to levofloxacin after piperacillin/tazobactam use is unclear. Further studies are necessary for better understanding of the relationship between piperacillin/tazobactam treatment and subsequent resistance to levofloxacin.
The levofloxacin-sensitive group was also sensitive to other antibiotics, especially ciprofloxacin. In our study, nearly all bacteria sensitive to levofloxacin also were sensitive to ciprofloxacin, making it an alternative treatment for S. maltophilia infection. 24 S. maltophilia isolates resistant to levofloxacin were also positive for genes associated with drug resistance to other antibiotics.
A previous study reported that the SmeA, SmeD, and SpgM genes are associated with multiple drugs resistance in S. maltophilia. 18 However, these observations were not consistent with our data. SmeA, SmeD, and SpgM may play minor roles in multiple drugs resistance of S. maltophilia, or other mechanisms may have contributed to the drug resistance of S. maltophilia found in our hospital. Further testing is necessary to fully elucidate these mechanisms of resistance.
In the previous studies, S. maltophilia resistance to TMP/SMX treatment has been associated with efflux pump genes such as BpeEF-OprC. 25 Although no study has yet shown SpgM to be related to TMP/SMX resistance, our study indicated that SMX-TMP resistance was associated with a lower frequency of SmeD and SpgM. SmeD and SpgM may not induce resistance to SMX/TMP, and other genes may induce resistance to SMX/TMP. When SmeD and SpgM are expressed, other genes related to SMX/TMP resistance may be suppressed and thus decrease SMX/TMP resistance.
Our study had many limitations. Because the sample size was small and all samples were from the same hospital, many risk factors did not reach statistical significance. Some genes commonly associated with drug resistance, such as Smqnr, a gene associated with quinolone resistance in some studies, were not detected in our study. 26, 27 We did not find any genes associated with levofloxacin resistance in our study.
In conclusion, except for previous piperacillin/tazobactam antibiotic treatment, we found no significant associations between S. maltophilia drug resistance to levofloxacin and other risk factors in our patients. Three genes, including SmeA, SmeD, and SpgMdpreviously reported to be associated with levofloxacin resistancedwere not significantly associated with the resistant group in our study. Other genes may contribute to levofloxacin resistance. More studies including larger case numbers and more drug resistant genes are necessary to understand fully the causes and risk factors of drug resistance in S. maltophilia.
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